Ravi R Jhaveri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2356637/publications.pdf

Version: 2024-02-01

257101 223531 2,327 114 24 46 citations h-index g-index papers 114 114 114 3272 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Conversations With the Editors: Learning and Teaching the Concepts of Food as Medicine and Culinary Medicine. Clinical Therapeutics, 2022, , .	1.1	1
2	Beyond Influenza Vaccination: Expanding Infrastructure for Hospital-based Pediatric COVID-19 Vaccine Delivery. Clinical Therapeutics, 2022, 44, 450-455.	1.1	6
3	Celebration and Acknowledgment at a Time of Transition. Clinical Therapeutics, 2022, , .	1.1	О
4	Our Pledge to Assemble a More Diverse and Inclusive Editorial Team at Clinical Therapeutics. Clinical Therapeutics, 2022, 44, 1-2.	1.1	3
5	Severity of Acute COVID-19 in Children & Severity of Acute COVID-19 in Children & Severity Old March 2020 to December 2021. Pediatrics, 2022, 149, .	1.0	51
6	Elimination Means <i>Everyone</i> : Targeting Hepatitis C in Infants and Pregnant Patients. Clinical Infectious Diseases, 2022, , .	2.9	2
7	Receiver operating characteristic curves and confidence bands for support vector machines. Biometrics, 2021, 77, 1422-1430.	0.8	8
8	Trisomy 21 and Coronavirus Disease 2019 in Pediatric Patients. Journal of Pediatrics, 2021, 228, 294-296.	0.9	18
9	Hepatitis C Virus in Children: Trying to Overcome the Domestic and Global Challenges of Cases and Cost. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 71-74.	0.6	2
10	OUP accepted manuscript. Journal of the Pediatric Infectious Diseases Society, 2021, , .	0.6	0
11	Disordered Eating Is All About Context. Clinical Therapeutics, 2021, 43, 1-2.	1.1	2
12	566 Identifying barriers to the inclusion of pregnant patients in hepatitis C research and treatment programs. American Journal of Obstetrics and Gynecology, 2021, 224, S358-S359.	0.7	1
13	Coronavirus disease 2019 vaccine hesitancy among children's hospital staff: A single-center survey. Infection Control and Hospital Epidemiology, 2021, 42, 775-777.	1.0	25
14	Coffee: More Than Just Your Morning Pick-Me-Up. Clinical Therapeutics, 2021, 43, 431-433.	1.1	0
15	The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning?. Clinical Therapeutics, 2021, 43, 549-556.	1.1	13
16	The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World. Clinical Therapeutics, 2021, 43, 702-710.	1.1	7
17	A Survey of Practices in the United States Regarding Hepatitis C Screening in Pregnant Women. Clinical Therapeutics, 2021, 43, 780-784.	1.1	1
18	Exploration and Ethical Analysis of Open-label Pediatric Vaccine Trials in a Pandemic. Clinical Therapeutics, 2021, 43, e163-e172.	1.1	3

#	Article	IF	CITATIONS
19	Responsible Inclusion of Pregnant Individuals in Eradicating HCV. Hepatology, 2021, 74, 1645-1651.	3.6	17
20	Our Response to the Obesity Crisis Reflects Our Bias as a Society. Clinical Therapeutics, 2021, 43, 1135-1137.	1.1	0
21	Staving Off Our Cognitive Decline: Another Benefit of All Those Hours in the Gym. Clinical Therapeutics, 2021, 43, 917-918.	1.1	0
22	Conversations With the Editors: The Emergence of Variants Amid Population-Wide SARS-CoV-2 Vaccination Efforts: How Much Should We Worry?. Clinical Therapeutics, 2021, 43, 1630-1635.	1.1	1
23	REPLY:. Hepatology, 2021, 74, 2312-2313.	3.6	0
24	Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 937-939.	0.6	5
25	Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study. The Lancet Global Health, 2021, 9, e1600-e1609.	2.9	26
26	How COVID-19 Is Helping Us Learn More About Diabetes Pathogenesis. Clinical Therapeutics, 2021, 43, 1435-1436.	1.1	1
27	Electronic Health Record Network Research in Infectious Diseases. Clinical Therapeutics, 2021, 43, 1668-1681.	1.1	5
28	Big Data and Behavioral Economics in Infectious Diseases. Clinical Therapeutics, 2021, 43, 1646-1648.	1.1	0
29	One Year of COVID-19 mRNA Vaccines: Incredible Progress and Unfinished Business. Clinical Therapeutics, 2021, 43, 2041-2043.	1.1	3
30	477. Increased Referrals for New PFAPA (Aphthous Stomatitis, Pharyngitis, Adenitis) Diagnosis During the COVID-19 Pandemic. Open Forum Infectious Diseases, 2021, 8, S340-S341.	0.4	1
31	91. Knowledge, Attitudes, and Practice of Antibiotic Prescribing among Nurse Practitioners. Open Forum Infectious Diseases, 2021, 8, S160-S161.	0.4	0
32	1177. Vaccinate Lurie (VaLu) a QI Project to Improve Pediatric Pre-Transplant Immunization Rates. Open Forum Infectious Diseases, 2021, 8, S680-S681.	0.4	0
33	777. Implementation of Antimicrobial Impregnated Catheters to Reduce Central Line Associated Bloodstream Infections (CLABSI) in a Pediatric Setting. Open Forum Infectious Diseases, 2021, 8, S485-S486.	0.4	0
34	Combating Antimicrobial Resistance: Going Beyond New Antibiotics. Clinical Therapeutics, 2020, 42, 1625-1627.	1.1	0
35	Conversations With the Editors: Hepatitis C Virus—Where are We Now and Where Do We Go From Here?. Clinical Therapeutics, 2020, 42, 1425-1432.	1.1	1
36	Conversations With the Editors: Promoting Science and Combating Antiscience: A Focus on Communication Strategies. Clinical Therapeutics, 2020, 42, 2242-2247.	1.1	2

#	Article	IF	Citations
37	Conversations With the Editors: Promoting Science and Combating Anti-science: The Past and Present of the Antivaccine Movement. Clinical Therapeutics, 2020, 42, 2248-2252.	1.1	3
38	Screening for Hepatitis C Virus: How Universal Is Universal?. Clinical Therapeutics, 2020, 42, 1434-1441.	1.1	7
39	Hepatitis C in 2020. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 407-417.	0.9	21
40	Patient Safety. Clinical Therapeutics, 2020, 42, 551-553.	1.1	1
41	We Need a New National Strategy for Hepatitis C Virus Screening. Pediatrics, 2020, 145, .	1.0	3
42	The Skin–Immune System Interface. Clinical Therapeutics, 2020, 42, 729-730.	1.1	0
43	Echoes of 2009 H1N1 Influenza Pandemic in the COVID Pandemic. Clinical Therapeutics, 2020, 42, 736-740.	1.1	21
44	569. A Multidisciplinary Approach to the Pre-evaluation Process of Pediatric Solid Organ Transplant Patients. Open Forum Infectious Diseases, 2020, 7, S349-S349.	0.4	0
45	Update on Associated Risk Factors, Diagnosis, and Management of Recurrent Urinary Tract Infections in Children. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 152-159.	0.6	12
46	Myths and Misconceptions: Varicella-Zoster Virus Exposure, Infection Risks, Complications, and Treatments. Clinical Therapeutics, 2019, 41, 1816-1822.	1.1	7
47	Focusing on the Host Side of Host–Pathogen Interactions. Clinical Therapeutics, 2019, 41, 1904-1906.	1.1	1
48	"Here Today, Gone Tomorrow―or "Here Today, Stay a Long While― The Divergent Paths of Two Host Factors Important in Viral Infections. Clinical Therapeutics, 2019, 41, 1907-1911.	1.1	3
49	Reply to McAuley and Close. Clinical Infectious Diseases, 2019, 69, 557-558.	2.9	0
50	Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection. Journal of Pediatrics, 2019, 207, 90-96.	0.9	35
51	The Time Has Come to Stop Using Vancomycin as Part of Empiric Therapy for Meningitis. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 92-93.	0.6	7
52	Missed hepatitis B birth dose vaccine is a risk factor for incomplete vaccination at 18 and 24 months. Journal of Infection, 2019, 78, 134-139.	1.7	18
53	The Cost of Vancomycin and Piperacillin/Tazobactam Treatment. JAMA Pediatrics, 2018, 172, 494.	3.3	1
54	Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV. Current HIV/AIDS Reports, 2018, 15, 155-161.	1.1	15

#	Article	IF	CITATIONS
55	Update on the management of hepatitis B and C infections in the neonatal period. Seminars in Perinatology, 2018, 42, 185-190.	1.1	6
56	Reply to Walker et al. Clinical Infectious Diseases, 2018, 67, 984-984.	2.9	1
57	These Findings Are Not Consistent With National Data. Pediatrics, 2018, 141, e20173679A.	1.0	1
58	Call to Action: Prevention of Mother-to-Child Transmission of Hepatitis B in Africa. Journal of Infectious Diseases, 2018, 217, 1180-1183.	1.9	26
59	Individual State Hepatitis C Data Supports Expanding Screening Beyond Baby Boomers to All Adults. Gastroenterology, 2018, 154, 1850-1851.e2.	0.6	33
60	Fever Without Localizing Signs. , 2018, , 115-117.e1.		0
61	Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse. Journal of Pediatrics, 2018, 192, 159-164.	0.9	38
62	Prospective Assessment of Pill-Swallowing Ability in Pediatric Patients. Clinical Pediatrics, 2018, 57, 300-306.	0.4	8
63	2217. Demographic Trends and Health Care Utilization Among Children With Hepatitis C Virus Infection. Open Forum Infectious Diseases, 2018, 5, S655-S655.	0.4	0
64	Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases, 2018, 67, 1477-1492.	2.9	509
65	Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now. Clinical Infectious Diseases, 2018, 67, 1493-1497.	2.9	45
66	Hot Topics in Viral Infections. Clinical Therapeutics, 2018, 40, 1230-1233.	1.1	1
67	Live Attenuated Influenza Vaccine: Is Past Performance a Guarantee of Future Results?. Clinical Therapeutics, 2018, 40, 1246-1254.	1.1	10
68	Unique Challenges of Hepatitis C in Infants, Children, and Adolescents. Clinical Therapeutics, 2018, 40, 1299-1307.	1.1	22
69	A Feasibility Trial of Home Administration of Intranasal Vaccine by Parents to Eligible Children. Clinical Therapeutics, 2017, 39, 204-211.e4.	1.1	6
70	Vaccines. Clinical Therapeutics, 2017, 39, 1516-1518.	1.1	1
71	Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele. Clinical Infectious Diseases, 2017, 65, 999-1005.	2.9	29
72	Anti-infective Dosing in Special Populations. Clinical Therapeutics, 2016, 38, 1928-1929.	1.1	1

#	Article	IF	Citations
73	Hepatitis C Mother-to-Child Transmission. NeoReviews, 2016, 17, e521-e531.	0.4	O
74	Evaluation and Management of Febrile Children. JAMA Pediatrics, 2016, 170, 794.	3.3	39
75	Evaluating Guideline-Recommended Antibiotic Practices for Childhood Respiratory Infections. Clinical Pediatrics, 2016, 55, 118-121.	0.4	3
76	Reductions in neonatal listeriosis: "Collateral benefit―of Group B streptococcal prophylaxis?. Journal of Infection, 2016, 72, 317-323.	1.7	21
77	Tablet/Capsule Size Variation Among the Most Commonly Prescribed Medications for Children in the USA: Retrospective Review and Firsthand Pharmacy Audit. Paediatric Drugs, 2016, 18, 65-73.	1.3	8
78	A Prospective Pilot Study on the Systemic Absorption of Oral Vancomycin in Children With Colitis. Journal of Pediatric Pharmacology and Therapeutics, 2016, 21, 426-431.	0.3	8
79	Outcome of infections with extended spectrum beta-lactamase producing organisms in children. Journal of Pediatric Infectious Diseases, 2015, 03, 229-233.	0.1	1
80	CA-MRSA brain abscess in a healthy infant. Journal of Pediatric Infectious Diseases, 2015, 06, 071-075.	0.1	0
81	A Pilot Study of the Pediatric Oral Medications Screener (POMS). Hospital Pediatrics, 2015, 5, 586-590.	0.6	5
82	Reliability of risk-based screening for hepatitis C virus infection among pregnant women in Egypt. Journal of Infection, 2015, 70, 512-519.	1.7	26
83	Effectiveness of Pediatric Pill Swallowing Interventions: A Systematic Review. Pediatrics, 2015, 135, 883-889.	1.0	47
84	Prevention of Hepatitis B Virus Vertical Transmission: Time for the Next Step. Pediatrics, 2015, 135, e1286-e1287.	1.0	1
85	Hepatitis C Virus (HCV) Vertical Transmission in 12-Month-Old Infants Born to HCV-Infected Women and Assessment of Maternal Risk Factors. Open Forum Infectious Diseases, 2015, 2, ofv089.	0.4	26
86	Frequency and outcomes of Moraxella catarrhalis bacteremia in children. Journal of Pediatric Infectious Diseases, 2015, 02, 095-100.	0.1	0
87	Outbreak Management. Clinical Therapeutics, 2015, 37, 2400-2401.	1.1	1
88	961Reductions of Listeria Infections in Infants: Collateral benefit of Prophylaxis against Group B Streptococcus?. Open Forum Infectious Diseases, 2014, 1, S280-S280.	0.4	0
89	Hepatitis C Virus in Pregnancy and Early Childhood: Current Understanding and Knowledge Deficits. Journal of the Pediatric Infectious Diseases Society, 2014, 3, S13-S18.	0.6	18
90	Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. Clinical Science, 2014, 126, 845-855.	1.8	22

#	Article	IF	Citations
91	Protection Against Hepatitis C and Other Enveloped Viruses? Another Reason Why "Breast Is Best". Journal of Infectious Diseases, 2013, 208, 1932-1933.	1.9	1
92	Pediatric-Specific Antimicrobial Susceptibility Data and Empiric Antibiotic Selection. Pediatrics, 2012, 130, e615-e622.	1.0	39
93	Lipid Droplet Binding of Hepatitis C Virus Core Protein Genotype 3. ISRN Gastroenterology, 2012, 2012, 1-7.	1.5	7
94	Diagnosis and Management of Hepatitis C Virus–infected Children. Pediatric Infectious Disease Journal, 2011, 30, 983-985.	1.1	21
95	Management of the Non–Toxic-Appearing Acutely Febrile Child: A 21st Century Approach. Journal of Pediatrics, 2011, 159, 181-185.	0.9	28
96	Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. Hepatology, 2011, 54, 1580-1590.	3.6	42
97	All-Cause, Liver-Related, and Non-Liver-Related Mortality Among HCV-Infected Individuals in the General US Population. Clinical Infectious Diseases, 2011, 53, 150-157.	2.9	133
98	Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Laboratory Investigation, 2010, 90, 1690-1703.	1.7	104
99	Performance of the ASTâ€toâ€Platelet Ratio Index as a Noninvasive Marker of Fibrosis in Pediatric Patients With Chronic Viral Hepatitis. Journal of Pediatric Gastroenterology and Nutrition, 2010, 50, 344-346.	0.9	58
100	Changing Epidemiology of Serious Bacterial Infections in Febrile Infants without Localizing Signs. PLoS ONE, 2010, 5, e12448.	1.1	83
101	Domain 3 of Hepatitis C Virus Core Protein Is Sufficient for Intracellular Lipid Accumulation. Journal of Infectious Diseases, 2009, 200, 1781-1788.	1.9	18
102	Recombinant adenoviruses expressing Steatosis-associated Hepatitis C virus genotype 3 Core protein produce intracellular lipid accumulation in cultured and primary hepatocytes. Virus Research, 2009, 139, 127-130.	1.1	5
103	Specific Polymorphisms in Hepatitis C Virus Genotype 3 Core Protein Associated with Intracellular Lipid Accumulation. Journal of Infectious Diseases, 2008, 197, 283-291.	1.9	65
104	Correspondence. Hepatology, 2007, 46, 280-280.	3.6	5
105	Endoplasmic reticulum stress, hepatocyte CD1d and NKT cell abnormalities in murine fatty livers. Laboratory Investigation, 2007, 87, 927-937.	1.7	91
106	The burden of hepatitis C virus infection in children: Estimated direct medical costs over a 10-year period. Journal of Pediatrics, 2006, 148, 353-358.	0.9	90
107	Pneumococcal Empyema. Pediatric Infectious Disease Journal, 2006, 25, 854.	1.1	3
108	Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology, 2005, 42, 1406-1413.	3.6	74

#	Article	IF	CITATIONS
109	Effect of Heptitis C Virus Core Protein on Cellular Gene Expression: Specific Inhibition of Cyclooxygenase 2. Journal of Infectious Diseases, 2005, 191, 1498-1506.	1.9	17
110	Hepatitis B and C Viruses in Infants and Young Children. Seminars in Pediatric Infectious Diseases, 2005, 16, 296-305.	1.7	56
111	Varicella-zoster virus reactivation in the central nervous system. Pediatric Infectious Disease Journal, 2004, 23, 185-186.	1.1	8
112	Varicella-zoster virus: an overlooked cause of aseptic meningitis. Pediatric Infectious Disease Journal, 2003, 22, 96-97.	1.1	51
113	Erythema Migrans After Ceftriaxone Treatment of Aseptic Meningitis Caused by Borrelia Burgdorferi. Pediatric Infectious Disease Journal, 2001, 20, 1010-1012.	1.1	5
114	<i>Staphylococcus aureus</i> -Associated Glomerulonephritis and Chronic Granulomatous Disease in an Adolescent Male. Journal of the Pediatric Infectious Diseases Society, 0, , .	0.6	0